| Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. PEOVGOG Investigators New England Journal of Medicine 381 (25), 2391-2402, 2019 | 2047 | 2019 |
| Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised … E Pujade-Lauraine, JA Ledermann, F Selle, V Gebski, RT Penson, ... The lancet oncology 18 (9), 1274-1284, 2017 | 1821 | 2017 |
| Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial RL Coleman, AM Oza, D Lorusso, C Aghajanian, A Oaknin, A Dean, ... The Lancet 390 (10106), 1949-1961, 2017 | 1773 | 2017 |
| Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial EM Swisher, KK Lin, AM Oza, CL Scott, H Giordano, J Sun, GE Konecny, ... The lancet oncology 18 (1), 75-87, 2017 | 1232 | 2017 |
| Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer. MBJ Colombo N, Dubot C, Lorusso D, Caceres MV, Hasegawa K, Shapira-Frommer R ... New England Journal of Medicine 385 (20), 1856-1867, 2021 | 779 | 2021 |
| Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study … RL Coleman, MF Brady, TJ Herzog, P Sabbatini, DK Armstrong, JL Walker, ... The Lancet Oncology 18 (6), 779-791, 2017 | 668 | 2017 |
| Ovarian cancer, version 2.2020, NCCN clinical practice guidelines in oncology DK Armstrong, RD Alvarez, JN Bakkum-Gamez, L Barroilhet, K Behbakht, ... Journal of the National Comprehensive Cancer Network 19 (2), 191-226, 2021 | 619 | 2021 |
| Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer CM Phelan, KB Kuchenbaecker, JP Tyrer, SP Kar, K Lawrenson, ... Nature genetics 49 (5), 680-691, 2017 | 466 | 2017 |
| Adjuvant chemotherapy plus radiation for locally advanced endometrial cancer D Matei, V Filiaci, ME Randall, D Mutch, MM Steinhoff, PA DiSilvestro, ... New England Journal of Medicine 380 (24), 2317-2326, 2019 | 443 | 2019 |
| Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor … AN Fader, DM Roque, E Siegel, N Buza, P Hui, O Abdelghany, ... Journal of Clinical Oncology 36 (20), 2044-2051, 2018 | 436 | 2018 |
| Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian … O Kondrashova, M Nguyen, K Shield-Artin, AV Tinker, NNH Teng, ... Cancer discovery 7 (9), 984-998, 2017 | 406 | 2017 |
| Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer JK Chan, MF Brady, RT Penson, H Huang, MJ Birrer, JL Walker, ... New England Journal of Medicine 374 (8), 738-748, 2016 | 403 | 2016 |
| BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma KK Lin, MI Harrell, AM Oza, A Oaknin, I Ray-Coquard, AV Tinker, ... Cancer discovery 9 (2), 210-219, 2019 | 384 | 2019 |
| Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double … PLE Poveda A, Floquet A, Ledermann JA, Asher R, Penson RT, Oza AM, Korach J ... Lancet Oncology 22 (5), 620-631, 2021 | 365 | 2021 |
| Pembrolizumab in patients with microsatellite instability–high advanced endometrial cancer: results from the KEYNOTE-158 study DM O'Malley, GM Bariani, PA Cassier, A Marabelle, AR Hansen, ... Journal of Clinical Oncology 40 (7), 752-761, 2022 | 359 | 2022 |
| Ovarian cancer, version 1.2016, NCCN clinical practice guidelines in oncology RJ Morgan, DK Armstrong, RD Alvarez, JN Bakkum-Gamez, K Behbakht, ... Journal of the National Comprehensive Cancer Network 14 (9), 1134-1163, 2016 | 345 | 2016 |
| Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm … RL Coleman, D Lorusso, C Gennigens, A González-Martín, L Randall, ... The Lancet Oncology 22 (5), 609-619, 2021 | 332 | 2021 |
| Identification of six new susceptibility loci for invasive epithelial ovarian cancer KB Kuchenbaecker, SJ Ramus, J Tyrer, A Lee, HC Shen, J Beesley, ... Nature genetics 47 (2), 164-171, 2015 | 325 | 2015 |
| A comprehensive overview of radioguided surgery using gamma detection probe technology SP Povoski, RL Neff, CM Mojzisik, DM O'Malley, GH Hinkle, NC Hall, ... World journal of surgical oncology 7, 1-63, 2009 | 284 | 2009 |
| Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated … AM Oza, AV Tinker, A Oaknin, R Shapira-Frommer, IA McNeish, ... Gynecologic oncology 147 (2), 267-275, 2017 | 273 | 2017 |
Bradley MonkProfessor of Gynecologic Oncology University of ArizonaВерификована је имејл адреса на usoncology.com
